We are currently making improvements to the Audible site. In an effort to enhance the accessibility experience for our customers, we have created a page to more easily navigate the new experience, available at the web address www.audible.com/access.
Call anytime(888) 283-5051
Forbes, January 03, 2011 | [Forbes]

Forbes, January 03, 2011

Welcome to Forbes for January 3rd, 2011 from Audible. This edition contains seven feature articles. The cover story is "Gene Machine" - Jonathan Rothberg's desktop decoder could kick off a revolution in medicine, food, energy, even consumer products--and ignite the next $100 billion technology market. Also, "The Man Behind Oprah" - David Zaslav is a longtime TV exec, but his new Oprah Winfrey Network will define him--one way or another.
Regular Price:$7.95
  • Membership Details:
    • First book free with 30-day trial
    • $14.95/month thereafter for your choice of 1 new book each month
    • Cancel easily anytime
    • Exchange books you don't like
    • All selected books are yours to keep, even if you cancel
  • - or -

Your Likes make Audible better!

'Likes' are shared on Facebook and Audible.com. We use your 'likes' to improve Audible.com for all our listeners.

You can turn off Audible.com sharing from your Account Details page.

OK

Publisher's Summary

Welcome to Forbes for January 3rd, 2011 from Audible. This edition contains seven feature articles.

The cover story is "Gene Machine" - Jonathan Rothberg's desktop decoder could kick off a revolution in medicine, food, energy, even consumer products--and ignite the next $100 billion technology market.

Also, "The Man Behind Oprah" - David Zaslav is a longtime TV exec, but his new Oprah Winfrey Network will define him--one way or another.

Next, "Under the Gun" - As Pentagon budgets shrink, Linda Hudson must transform defense giant BAE Systems. It will not be easy or cheap.

We'll also tell you about "Genome Hackers" - In an era of cheap gene scans and vast DNA databases, will consumers be able to keep their sensitive genetic information private?

Then, "Shrink It, Cure It" - GlaxoSmithKline Chief Andrew Witty has a plan to save the struggling drugmaker: Turn it into a collection of entrepreneurial biotech outfits.

Followed by "The Resurrection of Alan Schwartz" - Humbled by the collapse of Bear Stearns he has found a new life--and new challenges--in turning Guggenheim Partners into Wall Street's newest comer.

And in our final story "One Pharma Entrepreneur's Never Ending Quest" Lisa Conte mustered $200 million to make prescription drugs from plants. Payoff may be in sight.

Want to hear more Forbes?
Subscribe for one month or 12 months.
Get the latest issue.
Check out the complete archive.

© and (P) 2010 Forbes

What Members Say

Average Customer Rating

5.0 (1 )
5 star
 (1)
4 star
 (0)
3 star
 (0)
2 star
 (0)
1 star
 (0)
Overall
0 (0 )
5 star
 (0)
4 star
 (0)
3 star
 (0)
2 star
 (0)
1 star
 (0)
Story
0 (0 )
5 star
 (0)
4 star
 (0)
3 star
 (0)
2 star
 (0)
1 star
 (0)
Performance


There are no listener reviews for this title yet.

    There are no listener reviews for this title yet.

Report Inappropriate Content

If you find this review inappropriate and think it should be removed from our site, let us know. This report will be reviewed by Audible and we will take appropriate action.

CANCEL

Thank You

Your report has been received. It will be reviewed by Audible and we will take appropriate action.